Carolina Valente

Carolina Valente

Auto-generated profile, based on publicly available information

Carolina Valente

Departamento de Pneumologia, Centro Hospitalar Universitário de São João, Porto, Portugal

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2024 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
CCCatarina Gouveia Cardoso
Catarina Gouveia Cardoso
CVCarolina Valente
Carolina Valente
MSMariana Serino
Mariana Serino
IRInês Rodrigues
Inês Rodrigues
ACAndré Carvalho
André Carvalho
MDMarta Drummond
Marta Drummond
Objective: The frequency of obstructive sleep apnea (OSA) in patients with idiopathic pulmonary fibrosis (IPF) is high. The clinical course of non-IPF interstitial lung disease (ILD) can be similar to that of IPF. We sought to assess the frequency and predictors of OSA in patients with non-IPF fibrotic ILD, as well as the impact of positive airway pressure (PAP) therapy on the quality of life of such patients. Methods: This was a prospective study in which non-IPF fibrotic ILD patients underwent a home sleep apnea test. The patients with and without OSA were compared, and a multivariate logistic regression model was used to identify independent predictors of OSA. At 3 months after initiation of PAP therapy, we evaluated the participating patients for respiratory events, nocturnal hypoxemia, and changes in quality of life. Results: Of a total of 50 patients, 50% were male, and 76% were diagnosed with OSA. The mean age was 67.8 ± 8.3 years. The patients with OSA had significantly lower TLC (p = 0.033) and awake SpO2 (p = 0.023) than did those without OSA. In the multivariate logistic regression model, SpO2 (OR = 0.46; p = 0.016) and TLC (OR = 0.95; p = 0.026) remained significantly associated with OSA risk. A total of 12 patients received PAP therapy. At 3 months after initiation of PAP therapy, 91.7% were well controlled, Epworth Sleepiness Scale scores decreased significantly (p = 0.006), and emotional well-being tended to improve (p = 0.068). PAP therapy corrected nocturnal hypoxemia in all patients. Conclusions: We found a high frequency of OSA in patients with non-IPF fibrotic ILD. A low TLC was an independent predictor of a higher risk of OSA. PAP therapy can correct nocturnal hypoxemia. There should be a low threshold for suspicion of OSA and initiation of PAP therapy in patients with non-IPF fibrotic ILD.

3 June 2025 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
PFPedro Magalhães Ferreira1
Pedro Magalhães Ferreira1
RCRui Campos2
Rui Campos2
CVCarolina Valente1
Carolina Valente1
JFJoana Ferreira1
Joana Ferreira1
CFCláudia Freitas
Cláudia Freitas
2F2 Maria Gabriela O. Fernandes1
2 Maria Gabriela O. Fernandes1
Objectives: The 9th edition of the Tumor, Node, Metastasis (TNM-9) lung cancer classification is set to replace the 8th edition (TNM-8) starting in 2025. Key updates include the splitting of the mediastinal nodal category N2 into single- and multiple-station involvement, as well as the classification of multiple extrathoracic metastatic lesions as involving a single organ system (M1c1) or multiple organ systems (M1c2). This study aimed to assess how the TNM-9 revisions affect the final staging of lung cancer patients and how these changes correlate with overall survival (OS). Methods: This retrospective cohort study included patients diagnosed with lung cancer between 2018 and 2021, who were staged according to both TNM-8 and TNM-9 criteria. The staging classifications were analyzed and compared in relation to OS. Results: Among a total of 914 patients, 42 were re-staged using TNM-9. Of the 382 patients classified as stage IVB, 55.9% were reclassified as M1c2. Despite an absolute increase in mean OS for patients re-staged from IIB to IIA and from IIIA to IIB, the observed differences were not statistically significant. Median OS differed significantly both within stage IVB and between patients with M1c2 disease and other stage IV subgroups. Multi-organ metastatic disease was an independent predictor of poorer OS, regardless of age, sex, performance status, and oncologic treatment. Conclusions: TNM-9 improves prognostic accuracy in lung cancer. Although patients with multiple extrathoracic metastases involving different organ systems are not yet independently staged from IVB, they demonstrated significantly poorer OS compared to other advanced-stage patients.